Ligand Pharmaceuticals
LGND
262 hedge funds and large institutions have $1.97B invested in Ligand Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 101 increasing their positions, 87 reducing their positions, and 27 closing their positions.
19% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 27
16% more call options, than puts
Call options by funds: $999K | Put options by funds: $860K
16% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 87
2% more funds holding
Funds holding: 258 → 262 (+4)
1% more capital invested
Capital invested by funds: $1.96B → $1.97B (+$15.2M)
0.63% more ownership
Funds ownership: 96.59% → 97.22% (+0.63%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$17.8M |
| 2 |
RIM
Ranger Investment Management
Dallas,
Texas
|
+$12.2M |
| 3 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
+$5.06M |
| 4 |
Legal & General Group
London,
United Kingdom
|
+$5.01M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$4.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baird Financial Group
Milwaukee,
Wisconsin
|
-$7.42M |
| 2 |
Prudential Financial
Newark,
New Jersey
|
-$7.02M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
-$6.85M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.38M |
| 5 |
BlackRock
New York
|
-$2.92M |
LGND Hedge Fund Activity: Q1 2025 in Review
262 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2025, worth a combined $1.97B — up 0.78% from $1.96B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new LGND positions and 27 closed out — a net gain of 5 holders — while 101 added to existing stakes and 87 trimmed.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $17.8M. The largest seller was Baird Financial Group, cutting an estimated $7.42M.
- 262 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2025, up from 258 in Q4 2024.
- Funds reported $1.97B of Ligand Pharmaceuticals stock for Q1 2025, up 0.78% quarter-over-quarter.
- 32 funds opened new Ligand Pharmaceuticals positions in Q1 2025 and 27 closed out, a net change of +5 holders.
- The largest Ligand Pharmaceuticals buyer in Q1 2025 was Jacobs Levy Equity Management, an estimated $17.8M added.
- The largest Ligand Pharmaceuticals seller in Q1 2025 was Baird Financial Group, an estimated $7.42M sold.
Based on aggregated 13F filings for Q1 2025.